Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPPRESS: Brincidofovir for CMV Prevention in HCT Recipients
NCT01769170Phase 3Completed
- Sponsor
- Chimerix Inc.
- Start
- Aug 2013
- Primary completion
- Dec 2015
- Modality
- Metabolically Activated Prodrugs
- Countries
- 3
01
Overview
A Phase 3 trial of brincidofovir in cytomegalovirus infection (CMV), sponsored by Chimerix Inc.. Started Aug 2013; status: completed.
02
Drugs
brincidofovir
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT01769170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01769170.